Secondary Causes of Osteoporosis in Fracture Patients

Journal of Orthopaedic Trauma

Volumn 26, Issue 9, 2012, Pages e145-e152

  Bogoch, Earl R ^a   Elliot Gibson, Victoria ^a,b   Wang, Robert Y C ^a,b   Josse, Robert G ^b  

^a ST MICHAEL'S HOSPITAL   (Canada)

^b ST MICHAEL'S HOSPITAL   (Canada)

Author keywords

Deficiency; Fragility fracture; Insufficiency; Osteoporosis; Vitamin D

Indexed keywords

25 HYDROXYVITAMIN D; AMINOBISPHOSPHONATE; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCIUM; ETIDRONIC ACID; PARATHYROID HORMONE[1-34]; RALOXIFENE; UNCLASSIFIED DRUG; VITAMIN D;

ADULT; ALCOHOLISM; BLOOD EXAMINATION; BONE DENSITY; CIGARETTE SMOKING; CLINICAL ASSESSMENT; DRUG USE; ELECTRONIC MEDICAL RECORD; ENDOCRINE DISEASE; FEMALE; FRAGILITY FRACTURE; GASTROINTESTINAL DISEASE; HUMAN; HYPOGONADISM; KIDNEY DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; OSTEOPOROSIS; PREMATURE OVARIAN FAILURE; PREVALENCE; PRIORITY JOURNAL; REVIEW; VITAMIN BLOOD LEVEL; VITAMIN D DEFICIENCY;

AGED; BONE DENSITY; FEMALE; FRACTURES, BONE; HUMANS; MALE; MEDICAL AUDIT; MIDDLE AGED; OSTEOPOROSIS; PREVALENCE; RETROSPECTIVE STUDIES; URBAN POPULATION; VITAMIN D DEFICIENCY;

EID: 84864812850     PISSN: 08905339     EISSN: 15312291     Source Type: Journal    
DOI: 10.1097/BOT.0b013e3182323f2c     Document Type: Article

References (50)

1. Bogoch E, Elliot-Gibson V, Beaton DE, et al. Effective initiation of osteoporosis diagnosis and treatment in fragility fracture patients in an orthopaedic environment. J Bone Joint Surg Am. 2006;88:25-34.
2. Chevalley T, Hoffmeyer P, Bonjour JP, et al. An osteoporosis clinical pathway for the medical management of patients with low-trauma fracture. Osteoporos Int. 2002;13:450-455.
3. Harrington JT, Deal CL. Successes and failures in improving osteoporosis care after fragility fracture: results of a multiple-site clinical improvement project. Arthritis Rheum. 2006;5:724-728.
4. Majumdar SR, Rowe BH, Folk D, et al. A controlled trial to increase detection and treatment of osteoporosis in older patients with a wrist fracture. Ann Intern Med. 2004;141:366-373.
5. McLellan AR, Gallacher SJ, Fraser M, et al. The fracture liaison service: success of a program for the evaluation and management of patients with osteoporotic fracture. Osteoporos Int. 2003;14:1028-1034.
6. Tosi LL, Gliklich R, Kannan K, et al. The American Orthopaedic Association's “Own the Bone” initiative to prevent secondary fractures. J Bone Joint Surg Am. 2008;90:163-173.
7. Harrington JT, Lease J. Osteoporosis disease management for fragility fracture patients: new understandings based on three years' experience with an osteoporosis care service. Arthritis Rheum. 2007;57:1502-1506.
8. Leidig-Bruckner G, Hosch S, Dodidou P, et al. Frequency and predictors of osteoporotic fractures after cardiac or liver transplantation: a follow-up study. Lancet. 2001;357:342-347.
9. van Staa TP, Cooper C, Brusse LS, et al. Inflammatory bowel disease and the risk of fracture. Gastroenterology. 2003;125:1591-1597.
10. Neumann T, Samann A, Lodes S, et al. Glycaemic control is positively associated with prevalent fractures but not with bone mineral density in patients with type 1 diabetes. Diabet Med. 2011;28:872-875.
11. Malcolm JB, Derweesh IH, Kincade MC, et al. Osteoporosis and fractures after androgen deprivation initiation for prostate cancer. Can J Urol. 2007;14:3551-3559.
12. De Vries F, Bracke M, Leufkens HG. Fracture risk with intermittent high-dose oral glucocorticoid therapy. Arthritis Rheum. 2007;56:208-214.
13. Al-Osail AM, Sadat-Ali M, Al-Elq AH, et al. Glucocorticoid-related osteoporotic fractures. Singapore Med J. 2010;51:948-951.
14. Rejnmark L, Vestergard P, Brot C, et al. Increased fracture risk in normocalcemic postmenopausal women with high parathyroid hormone levels: a 16-year follow-up study. Calcif Tissue Int. 2011;88:238-245.
15. Painter SE, Kleerekoper M, Camacho PM. Secondary osteoporosis: a review of the recent evidence. Endocr Pract. 2006;12:436-445.
16. Dumitrescu B, van Helden S, den Broeke R, et al. Evaluation of patients with a recent clinical fracture and osteoporosis, a multidisciplinary approach. BMC Musculoskelet Disord. 2008;9:109.
17. Edwards BJ, Langman CB, Bunta AD, et al. Secondary contributors to bone loss in osteoporosis related hip fractures. Osteoporos Int. 2008;19:991-999.
18. Bours SP, van Geel TA, Geusens PP, et al. Contributors to secondary osteoporosis and metabolic bone diseases in patients presenting with a clinical fracture. J Clin Endocrinol Metab. 2011;96:1360-1367.
19. Fitzpatrick LA. Secondary causes of osteoporosis. Mayo Clinic Proc. 2002;77:453-468.
20. Orlic ZC, Raisz LG. Causes of secondary osteoporosis. J Clin Densitom. 1998;2:1-4.
21. Taxel P, Kenny A. Differential diagnosis and secondary causes of osteoporosis. Clin Cornerstone. 2000;2:11-19.
22. Cauley JA, LaCroix AZ, Wu L, et al. Serum 25-hydroxyvitamin D concentrations and risk for hip fractures. Ann Intern Med. 2008;149:242-250.
23. Nuti R, Martini G, Valenti R, et al. Vitamin D status and bone turnover in women with acute hip fracture. Clin Orthop Relat Res. 2004;422:208-213.
24. Ryan P, Dixon T. Prevalence of vitamin D inadequacy in patients attending a metabolic bone clinic in Medway. Curr Med Res Opin. 2006;22:211-216.
25. Simonelli C, Weiss TW, Morancey J, et al. Prevalence of vitamin D inadequacy in a minimal trauma fracture population. Curr Med Res Opin. 2005;21:1069-1074.
26. Przybelski R, Agrawal S, Krueger D, et al. Rapid correction of low vitamin D status in nursing home residents. Osteoporos Int. 2008;19:1621-1628.
27. Bacon C, Gamble G, Horne A, et al. High-dose oral vitamin D3 supplementation in the elderly. Osteoporos Int. 2009;20:1407-1415.
28. Larsen ER, Modekilde L, Foldspang A. Vitamin D and calcium supplementation prevents osteoporotic fractures in elderly community dwelling residents: a pragmatic population-based 3-year intervention study. J Bone Miner Res. 2004;19:370-378.
29. Trivedi DP, Doll R, Khaw KT. Effect of 4-monthly oral vitamin D3 (cholecalciferol) supplementation on fractures and mortality in men and women living in the community: randomized double-blind controlled trial. BMJ. 2003;326:469-472.
30. Chapuy MC, Arlot ME, Delmas PD, et al. Effect of calcium and cholecalciferol treatment for 3 years on hip fractures in elderly women. BMJ. 1994;308:1081-1082.
31. Lilliu H, Pamphile R, Chapuy MC, et al. Calcium-vitamin D3 supplementation is cost-effective in hip fractures prevention. Maturitas. 2003;44:299-305.
32. Maunsell Z, Wright D, Rainbow SJ. Routine isotope-dilution liquid chromatography-tandem mass spectrometry assay for simultaneous measurement of the 25-hydroxy metabolites of vitamin D2 and D3. Clin Chem. 2005;51:1683-1690.
33. Bischoff-Ferrari HA, Giovannucci E, Willett WC, et al. Estimation of optimal serum concentrations of 25-hydroxyvitamin D for multiple health outcomes. Am J Clin Nutr. 2006;84:18-28.
34. Bischoff-Ferrari HA, Shao A, Dawson-Hughes B, et al. Benefit-risk assessment of vitamin D supplementation. Osteoporos Int. 2010;21:1121-1132.
35. Beringer T, Heyburn G, Finch M, et al. Prevalence of vitamin D inadequacy in Belfast following fragility fracture. Curr Med Res Opin. 2006;22:101-105.
36. Gallacher SJ, McQuillian C, Harkness M, et al. Prevalence of vitamin D inadequacy in Scottish adults with non-vertebral fragility fractures. Curr Med Res Opin. 2005;21:1355-1361.
37. LeBoff MS, Hawkes WG, Glowacki J, et al. Vitamin D-deficiency and post-fracture changes in lower extremity function and falls in women with hip fractures. Osteoporos Int. 2008;19:1283-1290.
38. Nurmi I, Kaukonen JP, Luthje P, et al. Half of the patients with an acute hip fracture suffer from hypovitaminosis D: a prospective study in southeastern Finland. Osteoporos Int. 2005;16:2018-2024.
39. Sakuma M, Endo N, Oinuma T, et al. Vitamin D and intact PTH status in patients with hip fracture. Osteoporos Int. 2006;17:1608-1614.
40. Moniz C, Dew T, Dixon T. Prevalence of vitamin D inadequacy in osteoporotic hip fracture patients in London. Curr Med Res Opin. 2005;21:1891-1894.
41. Caplan GA, Scane AC, Francis RM. Pathogenesis of vertebral crush fractures in women. J R Soc Med. 1994;87:200-202.
42. Scane AC, Francis RM, Sutcliffe AM, et al. Case-control study of the pathogenesis and sequelae of symptomatic vertebral fractures in men. Osteoporos Int. 1999;9:91-97.
43. Baillie SP, Davison CE, Johnson FJ, et al. Pathogenesis of vertebral crush fractures in men. Age Ageing. 1992;21:139-141.
44. Jamal SA, Leiter RE, Bayoumi AM, et al. Clinical utility of laboratory testing in women with osteoporosis. Osteoporos Int. 2005;16:534-540.
45. Center JR, Bliuc D, Nguyen TV, et al. Risk of subsequent fracture after low-trauma fracture in men and women. JAMA. 2007;297:387-394.
46. Siminoski K, Leslie WD, Frame H, et al. Recommendations for bone mineral density reporting in Canada. Can Assoc Radiol J. 2005;56:178-188.
47. World Health Organization Collaborating Centre for Metabolic Bone DiseasesFRAX—WHO Fracture Risk Assessment Tool. Available at:. Accessed May 12, 2009.
48. Black DM, Delmas PD, Eastell R, et al.; for the HORIZON Pivotal Fracture Trial. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med. 2007; 356:1809-1822.
49. Black DM, Thompson DE, Bauter DC, et al.; for the FIT Research Group. Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. J Clin Endocrinol Metab. 2000; 85:4118-4124.
50. Silverman SL, Watts NB, Delmas PD, et al. Effectiveness of bisphosphonates on nonvertebral and hip fractures in the first year of therapy: the risedronate and alendronate (REAL) cohort study. Osteoporos Int. 2007;18:25-34.